Vanda Pharmaceuticals (NASDAQ:VNDA) Raised to “Buy” at StockNews.com

StockNews.com upgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a hold rating to a buy rating in a research note released on Sunday morning.

Separately, TheStreet lowered shares of Vanda Pharmaceuticals from a c- rating to a d rating in a research report on Thursday, February 8th.

Vanda Pharmaceuticals Trading Down 0.2 %

Shares of VNDA opened at $4.05 on Friday. Vanda Pharmaceuticals has a 12 month low of $3.30 and a 12 month high of $7.00. The firm’s 50 day moving average is $4.17 and its 200-day moving average is $4.05. The stock has a market capitalization of $233.04 million, a PE ratio of 81.02 and a beta of 0.76.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05. The business had revenue of $45.27 million for the quarter, compared to analysts’ expectations of $37.00 million. Vanda Pharmaceuticals had a net margin of 1.30% and a return on equity of 0.46%. Equities research analysts predict that Vanda Pharmaceuticals will post -0.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A number of hedge funds have recently modified their holdings of VNDA. Millennium Management LLC raised its stake in Vanda Pharmaceuticals by 1,089.5% during the fourth quarter. Millennium Management LLC now owns 1,783,745 shares of the biopharmaceutical company’s stock worth $13,182,000 after buying an additional 1,633,788 shares during the last quarter. Bank of America Corp DE raised its stake in Vanda Pharmaceuticals by 471.1% during the first quarter. Bank of America Corp DE now owns 1,631,140 shares of the biopharmaceutical company’s stock worth $11,075,000 after buying an additional 1,345,529 shares during the last quarter. State Street Corp raised its stake in Vanda Pharmaceuticals by 22.1% during the first quarter. State Street Corp now owns 4,551,912 shares of the biopharmaceutical company’s stock worth $30,907,000 after buying an additional 824,114 shares during the last quarter. BlackRock Inc. raised its stake in Vanda Pharmaceuticals by 7.0% during the second quarter. BlackRock Inc. now owns 10,810,016 shares of the biopharmaceutical company’s stock worth $71,238,000 after buying an additional 711,086 shares during the last quarter. Finally, Acadian Asset Management LLC raised its stake in Vanda Pharmaceuticals by 53.7% during the third quarter. Acadian Asset Management LLC now owns 1,750,655 shares of the biopharmaceutical company’s stock worth $7,559,000 after buying an additional 611,564 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.